JNJ - Goldman cuts 2seventy bio to neutral cites competition concerns
2024-06-06 10:47:18 ET
More on 2seventy bio
- 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
- 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
- Bristol-Myers posts Q1 beat despite growth headwinds
- Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
- Seeking Alpha’s Quant Rating on 2seventy bio